Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH)

NCT06160271 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT06160271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06160271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Central Hospital, Nancy, France
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2024
Completion date
June 1, 2027
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis